NL8700013A - Hybride plasminogeenactivatoren met verbeterde trombolytische eigenschappen en geneesmiddelen die deze plasminogeenactivatoren bevatten. - Google Patents

Hybride plasminogeenactivatoren met verbeterde trombolytische eigenschappen en geneesmiddelen die deze plasminogeenactivatoren bevatten. Download PDF

Info

Publication number
NL8700013A
NL8700013A NL8700013A NL8700013A NL8700013A NL 8700013 A NL8700013 A NL 8700013A NL 8700013 A NL8700013 A NL 8700013A NL 8700013 A NL8700013 A NL 8700013A NL 8700013 A NL8700013 A NL 8700013A
Authority
NL
Netherlands
Prior art keywords
scu
plasminogen activator
hybrid
plasminogen
fibrin
Prior art date
Application number
NL8700013A
Other languages
English (en)
Dutch (nl)
Original Assignee
Leuven Res & Dev Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leuven Res & Dev Vzw filed Critical Leuven Res & Dev Vzw
Priority to NL8700013A priority Critical patent/NL8700013A/nl
Priority to EP87202610A priority patent/EP0275606A1/en
Priority to JP63001802A priority patent/JPS63169987A/ja
Publication of NL8700013A publication Critical patent/NL8700013A/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
NL8700013A 1987-01-06 1987-01-06 Hybride plasminogeenactivatoren met verbeterde trombolytische eigenschappen en geneesmiddelen die deze plasminogeenactivatoren bevatten. NL8700013A (nl)

Priority Applications (3)

Application Number Priority Date Filing Date Title
NL8700013A NL8700013A (nl) 1987-01-06 1987-01-06 Hybride plasminogeenactivatoren met verbeterde trombolytische eigenschappen en geneesmiddelen die deze plasminogeenactivatoren bevatten.
EP87202610A EP0275606A1 (en) 1987-01-06 1987-12-22 Hybrid plasminogen activators with improved thrombolytic properties and drugs comprising these plasminogen activators
JP63001802A JPS63169987A (ja) 1987-01-06 1988-01-06 改良された血栓溶解特性を有するハイブリッドプラスミノーゲン活性化物質およびそれを含有する医薬

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL8700013A NL8700013A (nl) 1987-01-06 1987-01-06 Hybride plasminogeenactivatoren met verbeterde trombolytische eigenschappen en geneesmiddelen die deze plasminogeenactivatoren bevatten.
NL8700013 1987-01-06

Publications (1)

Publication Number Publication Date
NL8700013A true NL8700013A (nl) 1988-08-01

Family

ID=19849379

Family Applications (1)

Application Number Title Priority Date Filing Date
NL8700013A NL8700013A (nl) 1987-01-06 1987-01-06 Hybride plasminogeenactivatoren met verbeterde trombolytische eigenschappen en geneesmiddelen die deze plasminogeenactivatoren bevatten.

Country Status (3)

Country Link
EP (1) EP0275606A1 (ja)
JP (1) JPS63169987A (ja)
NL (1) NL8700013A (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108909A (en) * 1985-03-22 1992-04-28 Chiron Corporation Expression of TPA in mammalian cells
DE3684680D1 (de) * 1985-12-23 1992-05-07 Chiron Corp Peptidplasminogenaktivatoren.
US5204255A (en) * 1986-01-31 1993-04-20 Sagami Chemical Research Center Hybrid tissue plasminogen activator/urokinase polypeptides
CA1339546C (en) * 1986-11-12 1997-11-18 Thomas Quertermours Recombinant hybrid immunogloblin molecules an method of use
US5811265A (en) * 1988-08-19 1998-09-22 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
US5609869A (en) * 1988-08-19 1997-03-11 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
US9249406B2 (en) 2011-09-08 2016-02-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutated tissue plasminogen activators and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68561A (en) * 1982-05-05 1991-01-31 Genentech Inc Preparation of polypeptide with human tissue plasminogen activator function,processes for making it,and dna and transformed cell intermediates thereof
GB8334498D0 (en) * 1983-12-24 1984-02-01 Beecham Group Plc Compounds
DE3781420T2 (de) * 1986-01-31 1993-02-25 Sagami Chem Res Hybrides plasminogenaktivatoraehnliches polypeptid.

Also Published As

Publication number Publication date
JPS63169987A (ja) 1988-07-13
EP0275606A1 (en) 1988-07-27

Similar Documents

Publication Publication Date Title
Nelles et al. Characterization of recombinant human single chain urokinase-type plasminogen activator mutants produced by site-specific mutagenesis of lysine 158.
Nelles et al. Characterization of a fusion protein consisting of amino acids 1 to 263 of tissue-type plasminogen activator and amino acids 144 to 411 of urokinase-type plasminogen activator.
EP0155387B1 (en) Fibronolytically active hybrid protein, process for its preparation and pharmaceutical composition
Pennica et al. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli
ES2203668T3 (es) Variantes de glicosilacion del activador de plasminogeno de tejido con propiedades terapeuticas mejoradas.
CA2025900C (en) Derivative of tissue-type plasminogen activator
EP0196920B1 (en) Degraded species of tissue-type plasminogen activator, pharmaceutical composition and method of preparation
Lijnen et al. Biochemical and thrombolytic properties of a low molecular weight form (comprising Leu144 through Leu411) of recombinant single-chain urokinase-type plasminogen activator.
EP0538459A1 (en) Phospholipid-targeted thrombolytic agents
EP0355068A2 (en) Recombinant hybrid immunoglobulin molecules and their use
RU2143490C1 (ru) Бифункциональный вариант урокиназы, плазмида, содержащая синтетический структурный ген, кодирующий бифункциональную урокиназу, плазмида (варианты), способ получения плазмиды, способ получения бифункционального варианта урокиназы, тромболитическое средство
AU615450B2 (en) Novel fibrinolytic enzymes
US5242688A (en) Method of treating thromboembolic disorders by administration of diglycosylated t-pa variants
JPH04504799A (ja) 新規血栓溶解剤
NL8700013A (nl) Hybride plasminogeenactivatoren met verbeterde trombolytische eigenschappen en geneesmiddelen die deze plasminogeenactivatoren bevatten.
JP3329340B2 (ja) トロンビン活性化プラスミノーゲン誘導体
JP3045307B2 (ja) 活性化プロテインｃを生成するための細胞培養法
Collen et al. K1K2Pu, a recombinant t-PA/u-PA Chimera with increased thrombolytic potency, consisting of amino acids 1 to 3 and 87 to 274 of human tissue-type plasminogen activator (t-PA) and amino acids 138 to 411 of human single chain urokinase-type plasminogen activator (scu-PA). Purification in centigram quantities and conditioning for use in man
JP2002535372A (ja) プラスミノーゲンクリングル４領域フラグメントおよび利用法
US5234686A (en) Human tissue plasminogen activator consisting essentially of t-PA residues to 160 to 527, pharmaceutical compositions and methods of treatment
NL8701021A (nl) Humane t-pa(u-pa) substitutie-mutant eiwitten, daarvoor coderend recombinant dna, getransfecteerde gastheercellen, bereiding van de mutant eiwitten, en farmaceutische preparaten.
US5409700A (en) Pharmaceutical compositions comprising modified and unmodified plasminogen activators
US5723122A (en) Use of the protease domain of human plasminogen activator for the treatment of thromboembolic diseases
JP3153236B2 (ja) 端が切り取られた軽鎖を有する組換えプロテインｃ
Love et al. Attachment of an antifibrin antibody to the amino terminus of tissue-type plasminogen activator impairs stimulation by fibrin

Legal Events

Date Code Title Description
A1B A search report has been drawn up
BV The patent application has lapsed